Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available.
TransThera Sciences (Nanjing), Inc. has announced its plan to convert 44,971,128 domestic shares into H shares, representing approximately 11.33% of the company’s total issued shares. This move is part of the company’s strategy to enhance the liquidity and marketability of its shares by listing them on the Main Board of the Hong Kong Stock Exchange, pending necessary approvals from relevant authorities.
More about TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is focused on the development and commercialization of innovative therapies, with a market focus on converting domestic shares into H shares for trading on the Hong Kong Stock Exchange.
Average Trading Volume: 2,115,807
For a thorough assessment of 2617 stock, go to TipRanks’ Stock Analysis page.